Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to Exotics

Stock Information for Vivos Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vivos Inc

Vivos Inc. Provides IDE Submission Status Update - Conversion to Pre-Sub Filing Accepted by the FDA
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
Radiogel(TM) Precision Radionuclide Therapy(TM) Receives FDA Breakthrough Device Designation
Vivos Inc. Announces Certification of Three New IsoPet® Precision Radionuclide Therapy Regional Clinics
Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy
Vivos Inc Files a New Patent on Precision Radionuclide Therapy Support System Equipment
Vivos Inc Files a New Patent on the Hydrogel Component of IsoPet®/RadioGel(TM)
Vivos Inc. Announces a New IsoPet® Precision Radionuclide Therapy Regional Clinic for Equine Therapy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.